Available Until 1/30/2024

Intensive Studies for Recertification: Pediatric Pharmacy (Cert # L239020)

ACPE Numbers: Various – see listing below
Pre-Sale Date: 01/04/2023
Content Release Date: 02/01/2023
Expiration Date: 01/30/2024
Activity Type: Application-based
CE Credits: 4.0 (BPS and ACPE) contact hours
Activity Fee: $100 (ASHP member); $150 (non-member)

Activity Overview

The Intensive Study Package is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). Using a case-based approach, the activities provide high-level, interactive discussions on contemporary and emerging issues in pediatric pharmacy. 

The Pediatric Pharmacy Intensive Study Recertification Package consists of 3 activities (see table below) and provides up to 4.0 contact hours of continuing pharmacy education and/or recertification credit.   

These activities are part of the ASHP professional development program for BCPPS recertification approved by the BPS.  For pharmacists who maintain more than one certification, one of the activities is approved for multiple specialties (see table below).

These activities were presented as part of the 2022 Midyear Clinical Meeting. Learners who claimed ACPE credit for these activities as part of that meeting, should not claim ACPE credit again. 


The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Target Audience

These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in:

  • Disparities in Sickle Cell disease
  • Status epilepticus
  • Bias in primary literature

Recertification Credit

Board certified pharmacists are eligible to receive up to 4.0 contact hours of recertification credit for completing this package. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

Learning Activity

ACPE Number

Contact Hours (ACPE & BPS)

Forecasting the Future: Optimizing Care and Minimizing Disparities for Patients with Sickle Cell Disease (BCPPS)



→  Recertification Assessment (81% passing score required)

Status Epilepticus in Adults and Children (BCPPS, BCCCP, BCPS)



→  Recertification Assessment (73% passing score required)

Judging an Article by Its Cover: Assessing Bias in Primary Literature (BCPPS, BCCCP, BCPS)



→  Recertification Assessment (69% passing score required)

Learning Objectives

Forecasting the Future: Optimizing Care and Minimizing Disparities for Patients with Sickle Cell Disease
ACPE #: 0204-0000-22-236-H01-P

  • Summarize evidence-based recommendations in the treatment of sickle cell disease (SCD).
  • Recommend novel disease-modifying therapies for patients with SCD.
  • Select curative therapeutic modalities for patients with SCD.
  • Identify healthcare disparities that exist for patients with SCD. 

This activity is approved for Board Certified Pediatric Pharmacist (BCPPS) recertification credit. 

Status Epilepticus in Adults and Children
ACPE #: 0204-0000-22-241-H01-P

  • Contrast pharmacokinetic considerations in children compared to adults with status epilepticus.
  • Recommend initial benzodiazepine therapy for treatment of status epilepticus given a pediatric or adult patient case.
  • Contrast second phase medications for treatment of status epilepticus.
  • Given a patient case, evaluate third phase treatment options for status epilepticus.
  • Design a monitoring plan for a patient receiving treatment for status epilepticus. 

This activity is approved for Board Certified Critical Care Pharmacist (BCCCP), Board Certified Pediatric Pharmacy Specialist (BCPPS), and Board Certified Pharmacotherapy Specialist (BCPS) recertification credit. 

Judging an Article by Its Cover: Assessing Bias in Primary Literature
ACPE #: 0204-0000-22-269-H04-P 

  • Select appropriate research study design and types of errors associated with study methods.
  • Explain types of bias and how to prevent occurrence when developing methods of a clinical trial.
  • Based on study methodology and results of a clinical trial, determine how bias may affect analysis and interpretation of study results.
  • Compare and contrast current practice regarding bias and confounders when evaluating primary literature. 

This activity is approved for Board Certified Critical Care Pharmacist (BCCCP), Board Certified Pediatric Pharmacy Specialist (BCPPS), and Board Certified Pharmacotherapy Specialist (BCPS) recertification credit.


Faculty bios

Joshua J. Elder, PharmD, BCOP, BCPS
Clinical Specialist - Pediatric Heme/Onc/SCT
Director - PGY2 Oncology Pharmacy Residency
Norton Children's Hospital
Louisville, Kentucky 

Salia Farrokh, PharmD 
Neurocritical Care Clinical Pharmacist Specialist
Johns Hopkins Hospital
Ellicott City, Maryland

Emily K. Frederick, PharmD, BCPS 
Associate Professor
Sullivan University College of Pharmacy and Health Sciences
Louisville, Kentucky

Kaitlin M. Hughes, PharmD, BCPPS 
Clinical Pharmacist Pediatric Critical Care
Riley Hospital for Children at IU Health
Indianapolis, Indiana


Mary Hess, PharmD, BCCCP, FASHP, FCCM, FCCP*
Peter N. Johnson, PharmD, BCPPS, BCPS, FCCM, FPPAG*
Jamie L. Miller, PharmD, BCPPS*
Douglas Slain, PharmD, BCPS, FASHP* 
Paul M. Szumita, PharmD, BCCCP, BCPS, FASHP, FCCM* 
Jennifer L. Thackray, PharmD, BCPPS, BCPS*

*Content Matter Experts

Field Testers

Hakeem Abayomi, BS, PharmD, BCPS, BCPPS, BCIDP, BCCCP
Erin Anderson, PharmD
Elizabeth Autry, PharmD, BCPPS
Meghan Baldo, PharmD, BCPPS
Leanna Barker, PharmD, BCPPS
Jessica Bergsbaken, PharmD, BCPPS
Deanna Boone James, PharmD, CPh, BCPS, BCCCP
Alexander Brorby, PharmD, BCPS
Samantha Chang, PharmD
Da Won Choi, PharmD, BCPPS
Jesse Cramer, PharmD, BCPPS
Allie Dothager, PharmD, BCPS
Norm Fenn, PharmD, BCPS, BCPPS
Kristen Finical, PharmD, BCPPS
Adam Gaines, PharmD BCPS
Aaron Harthan, PharmD, BCPPS
Mylinh Ho, PharmD, BCPS, BCCCP
Pui Man (Julia) Ho, PharmD, BCPPS
Katie Hughes, PharmD, BCPPS
Malia Kleespies, PharmD, BCPPS
Ekaterina Kurdyukova, PharmD, BCPPS
Courtney Lang, PharmD, BCPS, BCCCP
Dylan Mochizuki, PharmD, BCPPS
Cody Moseman, PharmD
Zarema Muratova, BCPPS
Ashley Nebbia, PharmD, BCPPS
Nicole Palazzolo, PharmD, BCPPS
Amanda Penland, PharmD, BCPPS
Alyssa Polotti, PharmD, BCCCP
Isabel Porto, PharmD, BCPPS
Christy Rooks, BCPS, BCCCP
Marie Rossique-Gonzalez, PharmD, BCPPS
Anna Simmont, PharmD, BCPS, BCPPS
Autumn Aspen Wall, PharmD, BCPPS
Abigail Yancey, PharmD, FCCP, BCPS


In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company. 

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience. 

No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company. 

Methods and CE Requirements

Activities which can be completed in any order. Each activity consists of audio, video, and/or PDFs and evaluations.  Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity. 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 


These activities were developed by ASHP.